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Summary
Microdeletions of the Y chromosome are the second most frequent genetic cause of
spermatogenetic failure in infertile men after the Klinefelter syndrome. The molecular
diagnosis of Y-chromosomal microdeletions is routinely performed in the workup of
male infertility in men with azoospermia or severe oligozoospermia. Since 1999, the
European Academy of Andrology (EAA) and the European Molecular Genetics Quality
Network (EMQN) support the improvement of the quality of the diagnostic assays by
publication of the laboratory guidelines for molecular diagnosis of Y-chromosomal
microdeletions and by offering external quality assessment trials. The present revision of
the 1999 laboratory guidelines summarizes the results of a Best Practice Meeting held in
Florence (Italy) in October 2003. The basic protocol for microdeletion screening
suggested in the 1999 guidelines proved to be very accurate, sensitive and robust. In the
light of the recent advance in the knowledge of the Y chromosome sequence and of the
mechanism of microdeletion it was agreed that the basic 1999 protocol, based on two
multiplex polymerase chain reactions each covering the three AZF regions, is still fully
valid and appropriate for accurate diagnosis.
Keywords: azoospermia, genetic testing, male infertility, microdeletion,
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Introduction
Microdeletions of the Y chromosome are a recently
discovered cause of spermatogenetic failure resulting in male
infertility. After the Klinefelter syndrome, Y-chromosomal
microdeletions are the second most frequent genetic cause of
male infertility. In the last decade many investigators have
described the occurrence of microdeletions in infertile
patients around the world and the molecular diagnosis of
deletions has become an important diagnostic test in the
workup of male infertility (Vogt et al., 1996; Vogt, 1998;
Krausz & McElreavey, 1999; Maurer & Simoni, 2000).
The portion of the male-specific region of the Y
chromosome (MSY), comprising 95% of the Y chromosome
and flanked by pseudoautosomal regions (Skaletsky et al.,
2003), which is affected by deletions has been classically
subdivided into three regions called AZFa, AZFb and AZFc,
respectively (Vogt et al., 1996). Microdeletions are relatively
frequent among infertile men, although the incidence can
vary considerably depending on the selection criteria of the
patients. Azoospermic men have a higher incidence of
microdeletions than oligozoospermic men and consequently
deletion frequency found in different laboratories may vary
from 2 to 10% (or even higher) reflecting the composition of
the study population (Krausz & McElreavey, 1999; Krausz
et al., 2001). Typically, routine laboratories receiving referrals
Correspondence: Prof. Dr Manuela Simoni, Institute of Repro-
ductive Medicine, Domagkstr.11, D – 40129 Mu¨nster, Germany.
E-mail: simoni@uni-muenster.de
international journal of andrology, 27:240–249 (2004)
 2004 Blackwell Publishing Ltd.
from outside institutions, without controlled patient selec-
tion, have a much lower incidence, <2%. Deletions of the
three AZF regions occur with different frequency. According
to the experience of the Institute of Reproductive Medicine
in Mu¨nster, based on 34 patients with deletions of the Y
chromosome, deletions of the AZFc region are the leading
group (79% of all deletions), followed by AZFb (9%), AZFbc
(6%), AZFa (3%) and AZFabc (XX male: 3%).
The published data and the experience of the last years
showed that diagnostic protocols can be quite different and
that inaccurate or wrong diagnoses occur as well, suggesting
the necessity of both standardization and quality control
(Simoni, 2001). Therefore, the European Academy of
Andrology (EAA) and the European Molecular Genetics
Quality Network (EMQN) jointly supported the publication
of the Laboratory guidelines for molecular diagnosis of
Y-chromosomal microdeletions (Simoni et al., 1999) and
started offering external quality control.
Four years after publication of the guidelines with the
now complete knowledge of the sequence of the
Y chromosome (Skaletsky et al., 2003) and of the mechan-
ism of microdeletions (Kamp et al., 2000; Sun et al., 2000;
Kuroda-Kawaguchi et al., 2001; Repping et al., 2002), it was
felt that the time for a revision was ripe and the experts in the
field convened together with users in a Best Practice
Meeting held in Florence (Italy) in October 2003. The
results of this meeting and the revised guidelines are now
summarized in this paper.
Structure of the male-specific region
of the Y chromosome (MSY)
The complete physical map and sequence of MSY are
now available (Skaletsky et al., 2003). This information was
obtained by sequencing and mapping 220 BAC clones
containing portions of the MSY from one man. The use of
only one individual was necessary because, because of the
presence of repetitive sequences with only minute differ-
ences characterizing the individual copies of each sequence
(sequence family variants, SFV), inter-individual allelic
variation or polymorphisms would have prevented the
accurate mapping of SFV necessary to allocate the BAC
clones. Three classes of sequences were found in MSY:
X-transposed (with 99% identity to the X chromosome),
X-degenerate (single-copy genes or pseudogene homologues
of X-linked genes) and ampliconic. Ampliconic sequences
are characterized by sequence pairs showing nearly complete
(>99.9%) identity, organized in massive palindromes.
According to current knowledge, the reference MSY
contains 156 transcription units including 78 protein-coding
genes encoding 27 proteins. Ampliconic sequences comprise
60 coding genes and 74 non-coding transcription units
mostly grouped in families and expressed mainly or only in
the testis. Ampliconic sequences recombine through gene
conversion, i.e. non-reciprocal transfer of sequence
information occurring between duplicated sequences within
the chromosome, a process which maintains the >99.9%
identity between repeated sequences organized in pairs in
inverted orientation within palindromes.
Besides maintaining the gene content, this peculiar
organization provides the structural basis for deletions and
rearrangements. Today it is believed that deletions almost
invariably arise through homologous recombination between
identical repeated sequences with loss of the genetic material
between them. Considering the architecture of the MSY,
several different deletions are hypothetically possible (Yen,
2001), some of which have indeed been identified in infertile
but also in fertile men (Repping et al., 2003; Fernandes et al.,
2004). Those deletions clinically relevant for male infertility,
as of today’s knowledge, are briefly described below.
Mechanism and type of deletions
Three discrete AZFa, AZFb and AZFc regions were
originally characterized by careful mapping of the MSY of a
large number of men with microdeletions when the sequence
of the Y chromosome was not completely known (Vogt et al.,
1996). Today the sequence of the MSY and the molecular
mechanism resulting in microdeletions have been clarified.
This resulted in a new model of deletions in which the AZFb
and AZFc regions are overlapping. In addition, the AZFb and
AZFbc deletions have been suggested to be the consequence of
at least three different deletions patterns (Repping et al., 2002)
(Fig. 1). No consensus about the model and, consequently,
nomenclature of deletions has been reached so far. From the
practical, clinical point of view this is, however, uninfluential
for the prognosis of the patient and, being aware of the current
knowledge, either nomenclature can be adopted.
The AZFa region is about 1100 kb long and contains the
single copy genes DFFRY (or USP9Y) and DBY. Recent
data obtained simultaneously by different groups identify the
origin of complete AZFa deletions in the homologous
recombination between identical sequence blocks within the
retroviral sequences in the same orientation HERVyq1 and
HERVyq2 (Blanco et al., 2000; Kamp et al., 2000; Sun
et al., 2000). Within these retroviruses, recombination can
occur in either one of two identical sequence blocks (ID1
and ID2), giving rise to two major pattern of deletions
slightly different in their precise breakpoints (Kamp et al.,
2000, 2001; Sun et al., 2000). In any case the complete
deletion of the AZFa region removes about 792 kb
including both USP9Y and DBY genes, the only two genes
in AZFa. Deletions involving only the USPY9 gene or the
DBY gene have been reported only by one group (Ferlin
et al., 1999; Foresta et al., 2000) and not found in >1600
patients tested elsewhere (Silber et al., 1998; Krausz et al.,
2003 and references therein). Moreover, the mechanism
responsible for such selective loss has not been elucidated.
The type and mechanism of deletions of the AZFb and
AZFc region have been recently clarified as well (Kuroda-
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Kawaguchi et al., 2001). Both regions together comprise 24
genes, most of which present in multiple copies for a total of
46 copies. The complete deletion of AZFb removes 6.2 Mb
(including 32 copies of genes and transcription units) and
results from homologous recombination between the palin-
dromes P5/proximal P1 (Repping et al., 2002). The AZFc
region includes 12 genes and transcription units, each present
in a variable number of copies making a total of 32 copies
(Repping et al., 2003). The classical complete deletion of
AZFc, the most frequent pattern among men with deletions
of the Y chromosome, removes 3.5 Mb, originates from the
homologous recombination between amplicons b2 and b4 in
palindromes P3 and P1, respectively and removes 21 copies
of genes and transcription units (Kuroda-Kawaguchi et al.,
2001). Deletions of both AZFb and AZFc together occur by
to two major mechanisms involving homologous recombi-
nation between P5/distal P1 (7.7 Mb and 42 copies
removed) or between P4/distal P1 (7.0 Mb, 38 copies
removed) (Repping et al., 2002).
Therefore, according to the present knowledge, the
following recurrent microdeletions of the Y chromosome
are clinically relevant and are found in men with oligo- or
azoospermia (Fig. 1):
• AZFa,
• AZFb (P5/proximal P1),
• AZFbc (P5/distal P1 or P4/distal P1),
• AZFc (b2/b4).
Given the palindromic structure of the MSY and the
presence of several amplicons which could undergo
recombination, other types of deletions are possible
(Yen, 2001). Some of them have been identified, although
their clinical significance has not yet been fully explored
(Fernandes et al., 2002; Repping et al., 2003).
Genotype/phenotype correlation
Y microdeletions are specific for spermatogenic failure as
no deletions have been reported in a large number of
normospermic men (Krausz et al., 2003). Although fertility
can be compatible with Y deletions, it simply reflects the fact
that natural fertilization may occur even with relatively low
sperm counts depending on the female partner’s fertility
status. For this reason, it is more appropriate to consider Y
deletions as a cause of oligo/azoospermia rather than cause of
infertililty.
Deletions of the entire AZFa region as described above
invariably result in complete sertoli cell only (SCO)
syndrome and azoospermia (Vogt et al., 1996; Krausz et al.,
2000; Kamp et al., 2001; Kleiman et al., 2001; Hopps et al.,
2003). Deletions of isolated genes of the AZFa region,
involving only the USPY9 gene or the DBY gene were
related to a variable testicular phenotype (Ferlin et al., 1999;
Foresta et al., 2000). Such deletions, however, have been
described only sporadically and need further confirmation by
other groups. The diagnosis of a complete deletion of the
AZFa region implies the virtual impossibility to retrieve
testicular sperm for intracytoplasmic sperm injection (ICSI).
Complete deletions of AZFb and AZFb+c (P5/proximal
P1, P5/distal P1, P4/distal P1) are characterized by a
histological picture of SCO or spermatogenetic arrest
resulting in azoospermia. Several reports have shown that,
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Figure 1. Schematic representation of the Y
chromosome and of the current deletion models.
The model proposed by Vogt et al. (1996) with
the subdivision into the three AZFa, AZFb and
AZFc regions is depicted on the left-hand side of
the chromosome. The model of Repping et al.
(2002) is represented on the right-hand side of
the chromosome. The location of the STS
primers suggested by the present guidelines is
indicated by dotted lines. As four copies of the
DAZ gene are normally present on the Y
chromosome, the STS primers sY254, sY255
amplify four loci in AZFc. The AZFc (b2/b4)
deletion is by far the most frequent type
(approximately 80%) of Y-chromosomal micro-
deletion found in men with oligo/azoospermia.
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similarly to the complete deletions of the AZFa region, no
sperm are found upon attempts of testicular sperm extraction
(TESE) in these patients (Krausz et al., 2000; Hopps et al.,
2003). As in the case of complete deletions of AZFa, a
diagnosis of complete deletions of AZFb or AZFb+c
(P5/proximal P1, P5/distal P1, P4/distal P1) is incompatible
with sperm retrieval and ICSI should not be recommended
to these patients.
Deletions of the AZFc region (b2/b4) are associated with
a variable clinical and histological phenotype (Reijo et al.,
1996; Luetjens et al., 2002; Oates et al., 2002). In general,
AZFc deletions are compatible with residual spermatogen-
esis. AZFc deletions can be found in men with azoospermia
or severe oligozoospermia and, in rare cases, can even be
transmitted naturally to the male offspring (Ku¨hnert et al.,
2004 and references therein). In men with azoospermia and
AZFc deletion there is a fairly good chance of retrieving
sperm from TESE and children can be conceived by ICSI
(Kent-First et al., 1996; Mulhall et al., 1997; Jiang et al.,
1999; Kamischke et al., 1999; Kleiman et al., 1999; Page
et al., 1999; Cram et al., 2000; van Golde et al., 2001; Oates
et al., 2002; Peterlin et al., 2002). The sons of these patients
will be AZFc-deleted.
Indications for molecular screening
of the Y chromosome
Diagnosis of a microdeletion of the Y chromosome
permits the cause of the patient’s azoospermia/oligozoosper-
mia to be established and to formulate a prognosis. In which
patients should molecular screening of the Y chromosome be
performed? The world literature, now based on several
thousands of patients screened, indicates that, as a rule,
clinically relevant deletions are found in patients with
azoospermia or sperm concentration <1 · 106/mL. Very
rarely, deletions can be found in infertile patients with sperm
concentration between 1 and 5 · 106/mL (Maurer &
Simoni, 2000; Foresta et al., 2001). Although the incidence
of microdeletions is higher when patients are selected by
testicular histology, e.g. SCO (Foresta et al., 2001; Kamp
et al., 2001), no absolute selection criteria can be given
according to which patients are candidates for molecular
analysis. In general, in patients with chromosomal abnor-
malities, obstructive azoospermia or hypogonadotropic
hypogonadism molecular analysis of the Y chromosome is
not indicated but, the usual clinical parameters such as
hormone levels, testicular volume, varicocele, maldescended
testis, infections, etc. do not have any predictive value
(Maurer et al., 2001; Frydelund-Larsen et al., 2002; Oates
et al., 2002; Tomasi et al., 2003). Patients with azoospermia
or severe oligozoospermia who may be candidate for ICSI or
TESE/ICSI should be offered deletion screening because
TESE should not be recommended in cases of complete
deletion of the AZFa region, or complete deletion of AZFb
or deletions of the AZFb+c regions. Moreover, microdele-
tions of the AZFc region are transmitted to the male offspring
if assisted reproduction is performed (Kent-First et al., 1996;
Mulhall et al., 1997; Jiang et al., 1999; Kamischke et al.,
1999; Kleiman et al., 1999; Page et al., 1999; Cram et al.,
2000; van Golde et al., 2001; Oates et al., 2002; Peterlin
et al., 2002). Therefore, the diagnosis of a deletion has
prognostic value and can influence therapeutic options.
Genetic counselling is mandatory in order to provide
information about the risk of producing a son with impaired
spermatogenesis. However, the exact phenotype cannot be
predicted entirely because of the different genetic back-
ground and the impact of environmental factors on
reproductive functions and on the fertility potential of father
and son. Concerns have been raised about the potential risk
for the offspring of developing 45,X0 Turner’s syndrome
and other phenotypic anomalies associated with sex chro-
mosome mosaicism, including ambiguous genitalia. Data on
men with Y microdeletions (Siffroi et al., 2000) and in
patients bearing a mosaic 46XY/45X0 karyotype with sexual
ambiguity and/or Turner stigmata (Patsalis et al., 2002)
suggest that some Yq microdeletions are associated with an
overall Y chromosomal instability which might result in the
formation of 45,X0 cell lines. Until now only 17 male and
18 female ICSI babies born from fathers affected by Yq
microdeletions have been reported (Kent-First et al., 1996;
Mulhall et al., 1997; Jiang et al., 1999; Kamischke et al.,
1999; Kleiman et al., 1999; Cram et al., 2000; van Golde
et al., 2001; Oates et al., 2002; Peterlin et al., 2002). It
appears that the children are phenotypically normal, except
for one son born with pulmonary atresia and a hypoplastic
right ventricle (Page et al., 1999) and no ambiguous genitalia
or Turner syndrome have been observed among them.
Considering that embryos bearing a 45,XO karyotype have a
higher risk of spontaneous abortion, it would be important
to know whether there is a higher incidence of spontaneous
abortion among the partners of Y deleted men. Until this
information is available, it should be mentioned to the
patients with caution.
In general, the indication for molecular diagnosis of
Y-chromosomal microdeletions remains an important clin-
ical decision which should be taken case by case and
clinicians should decide in which patients they regard this
diagnosis as worthwhile and meaningful.
Guidelines for diagnostic testing
Diagnostic testing of deletions is performed by polym-
erase chain reaction (PCR) amplification of selected regions
of the Y chromosome. MSY-specific STS primers amplify
both anonymous sequences of the chromosome or genes and
can be now mapped precisely (Skaletsky et al., 2003).
Although the map of the MSY is now known, virtually
nothing is known about the role of the individual genes and
transcription units in spermatogenesis and their causal role in
infertility. It has been shown that using STS primers specific
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for discrete genes does not increase the detection rate of
clinically relevant microdeletions in DNA samples from ICSI
candidates (Silber et al., 1998; Krausz et al., 1999, 2001;
Peterlin et al., 2002). In addition, the palindromic/ampl-
iconic structure of MSY makes this region particularly prone
to rearrangements and loss of genetic material, which should
not necessarily be regarded as pathological microdeletions
and might represent relatively common polymorphisms
(Repping et al., 2003; Fernandes et al., 2004). Therefore it
remains basically unimportant whether the STS primers used
amplify anonymous regions or specific MSY genes. What is
important for the diagnosis is that the panel of STS primers
are derived from regions of the Y chromosome, which are
not polymorphic and are well known to be deleted
specifically in men affected by oligo/azoospermia according
to the known, clinically relevant microdeletion pattern. The
sequence of MSY and the mechanism underlying the
microdeletions have shown definitely that a putative fourth
AZFd region postulated by Kent-First et al. (1999) and
considered in a popular commercial kit does not exist.
PCR format and internal quality control
The PCR amplification of genomic DNA for clinical
diagnosis requires strict compliance with good laboratory
practice and basic principles of quality control. Guidelines
for internal quality control should be carefully followed
when implementing the diagnostics of Y-chromosomal
microdeletions and can be downloaded at http://www.emqn.
org/bpguidelines.php (25.5.04).
In parallel to the patient’s DNA sample, a female sample
has to be processed as a control for DNA contamination
during the whole procedure. Each set of PCR reactions
should be carried out at least in duplex or, even better,
multiplex PCR. The multiplex format is helpful to distin-
guish a negative result from a technical failure through the
use of an internal control. An appropriate internal PCR
control in AZF diagnostics is the ZFX/ZFY gene because
the primers amplify a unique fragment both in male and
female DNA, respectively. External positive and negative
controls must be run in parallel with each multiplex, i.e. with
each set of primers. Appropriate positive and negative
controls are a DNA sample from a man with normal
spermatogenesis and from a woman, respectively. The DNA
sample from a normal man controls for sensitivity and
specificity of the assay. The female DNA sample controls for
specificity and for contamination. In addition, a water
sample, which contains all reaction components but water
instead of DNA, must be run with each set of primers. The
water sample controls for reagent contamination.
In summary, the diagnostics of Y-chromosomal micro-
deletions should be performed by multiplex (at least duplex)
PCR amplification of genomic DNA, using the ZFX/ZFY
as internal PCR control. A DNA sample from a fertile male
and from a women and a blank (water) control should be run
in parallel with each multiplex.
Basic set of STS primers
In principle, the analysis of only one non-polymorphic
STS locus in each AZF region is sufficient to determine
whether any STS deletion is present in AZFa, AZFb or
AZFc. However, analysing two STS loci in each region
reinforces diagnostic accuracy, as deletions involve well-
defined regions including many STS loci. Therefore, the
concept that at least two STS loci in each AZF region should
be analysed remains valid. Based on the experience of many
laboratories and the results of external quality control and
considering the multiplex PCR format, the first choice of
STS primers recommended in the first version of the
guidelines remains basically valid. These primers include:
For AZFa: sY84, sY86
For AZFb: sY127, sY134
For AZFc: sY254, sY255 (both in the DAZ gene)
These STS primers have been shown to give robust and
reproducible results in multiplex PCR reactions by several
laboratories and in external quality control trials. Moreover,
the SRY gene should be included in the analysis as a control
for the testis-determining factor on the short arm of the Y
chromosome and for the presence of Y-specific sequences
when the ZFY gene is absent (e.g. in XX males).
In summary, the set of PCR primers which should be
used in multiplex PCR reactions as best choice for the
diagnosis of microdeletion of the AZFa, AZFb and AZFc
region includes: sY14 (SRY), ZFX/ZFY, sY84, sY86,
sY127, sY134, sY254, sY255. The location of these primers
on the Y chromosome is indicated in Fig. 1.
The sequence of the primers and an example of a PCR
protocol are reported in the Appendix A and B. The use of
this primer set will enable the detection of almost all the
clinically relevant deletions and of over 95% of the deletions
reported in the literature in the three AZF regions and is
sufficient for routine diagnostics. Adoption of this favourite
set of primers by all laboratories is strongly recommended as
it allows a minimal standardization and good comparison of
laboratory performance and inter-laboratory variability.
Significance of the basic primer set and extension analysis
AZFa The molecular analysis of the AZFa region involves
the use of the two STS markers sY84 and sY86. Both
markers are located upstream of the USPY9 and DBY genes
and are anonymous. According to the pathogenic mechan-
ism of the deletion and current experience, once a deletion
of both sY84 and sY86 is detected, the probability of dealing
with a complete deletion approaches 100%. However, as
AZFa deletions are rather rare and it cannot be excluded that
even more rare, still unknown deletion patterns exist, when
such a deletion if found it is advisable to complete diagnosis
by determining whether the deletion is complete or not.
As indicated in the previous guidelines (Simoni et al.,
1999), determination of the extension of the deletion
(complete/not complete) can be performed by using the
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STS primers sY82(present), sY83(absent) for the proximal
border and sY87(absent), sY88(present) for the distal border. A
more sophisticated determination of the breakpoints can be
obtained with the protocol suggested by Kamp et al. (2001).
If only one of the two AZFa STS loci (only sY84 or only
sY86) is deleted and amplification failures can be excluded,
the AZFa region should be studied in more detail testing for
the presence/absence of the two AZFa genes (DBY and
USP9Y) and the borders according to the map provided by
Kamp et al. (2001). This event, however, is presently
considered to be extraordinarily rare.
AZFb (P5/proximal P1) The two anonymous markers
sY127 and sY134 are located in the median and distal part of
AZFb. According to the present knowledge, in the vast
majority of cases the deletion of both markers indicates a
complete deletion of the AZFb region. This might be
confirmed by using the following second choice markers:
sY105 (present) and sY114 (absent) for the proximal border
and sY143 (absent) and sY152 (present) for the distal border. If
one wishes to determine the breakpoints of the deletion more
precisely, in particular to check if the AZFb deletion
corresponds to the P5/proximal P1 pattern, which also
removes two copies of the DAZ gene (Fig. 1), the primers
described by Repping et al. (2002) should be used. However,
it should be pointed out that this is not required for routine
clinical diagnosis of a complete deletion of the AZFb region.
AZFc (b2/b4) The two markers sY254 and sY255 are
specific for the DAZ gene, which is present in four copies
arranged in two complexes of two genes each in head-to-
head orientation located in the palindromes P2 and P1
respectively in the reference MSY sequence (Saxena et al.,
2000). The absence of both markers indicates deletion of the
entire AZFc region, which removes all copies of DAZ.
According to current knowledge, the deletion of only one of
these two markers is impossible and should be always
regarded as a methodological error. Deletion of individual
copies of the DAZ gene is possible but cannot be explored
with this protocol. Deletions of only two copies of the DAZ
gene have been reported both in infertile and in fertile men
(Fernandes et al., 2002; de Vries et al., 2002; Repping et al.,
2003). As the pathophysiological meaning of partial deletions
of the AZFc region remains to be determined, this analysis
should be considered experimental and is currently not
recommended for routine purposes.
The experience accumulated until now has shown that
when both markers sY254 and sY255 are deleted, a diagnosis
of complete deletion of the AZFc region can be made. As
the histological picture of the testis is variable in such cases
(Vogt et al., 1996; Luetjens et al., 2002) and sperm can be
found in the testis and/or in the ejaculate, TESE/ICSI can
be attempted in these patients. Some studies have shown that
the AZFc deletion pattern is rather constant, although not
always identical (Kuroda-Kawaguchi et al., 2001; Luetjens
et al., 2002). The primers indicated by Kuroda-Kawaguchi
et al. (2001) permit the user to determine if the deletion
corresponds to the b2/b4 pattern. This analysis, however,
will not change the prognosis for the patient and is not
necessary for routine purposes.
AZFbc (P5/distal P1 or P4/distal P1) The complete
deletion of both AZFb and AZFc regions is indicated by the
lack of amplification of all four markers sY127, sY134,
sY254 and sY255. The use of more specific markers as
indicated by Repping et al. (2002) determine whether the
deletion corresponds to the P5/distal P1 or P4/distal P1
pattern but is not necessary for clinical routine, as in view of
current knowledge this will not change the prognosis for
these patients.
Interpretation of the results, control and repetition of the test
The protocol suggested by these guidelines (see appendix
A) has been conceived and optimized so that each of the two
multiplex reactions contains a marker for each AZF region.
Thus, when a complete deletion occurs in a sample both
PCR reactions should show the lack of amplification for the
marker specific for that region. While partial deletions of the
AZFa and AZFb region, as indicated by the lack of
amplification of only one marker for the relevant region,
are possible, the elective deletion of only sY254 or sY255
should always be regarded as a methodological error. If only
one marker for AZFa or AZFb is deleted, the deletion must
first be carefully confirmed (see below) and then the entire
region should be studied in more detail. This event,
however, is presently regarded as exceptional.
The PCR conditions should be carefully optimized in each
laboratory according to the equipment available (e.g. type of
Thermocycler) and DNA quality. If the result is ambiguous
and/or a technical failure is suspected, the multiplex reaction
should be repeated. If the multiplex does not work for a
specific DNA sample, the primer set may be run in simplex
reactions. If the results of both multiplex PCR consistently
speak in favour of a deletion, the deletion is confirmed. If the
results of the two multiplexes are not in agreement, the whole
set of primers should be repeated in simplex PCR, as there is
no reason to repeat the test in the same manner. It is known
that simplex PCR is less subject to amplification failure and it is
strongly advised to repeat the amplification at a lower
annealing temperature. There is no general advice as to the
number of repetitions. The test should be repeated until the
results are clear and reproducible (good laboratory practice).
Reporting
Reports should be written in a standardized format and
should be clear to the non-specialist. Guidelines on how to
write reports on the outcome of molecular genetics
investigations on a patient can be found at the web site:
http://www.emqn.org/bpguidelines.php
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In general, reports must be clear, concise, accurate, fully
interpretative, credible and authoritative. Reports should be
typed, word-processed or produced by computer. Hand-
written reports are not acceptable. Reports must include the
following information:
• Clear identification of the laboratory.
• Date of referral and reporting.
• Patient identification: full name, date of birth and unique
laboratory accession/identification number.
• Restatement in some form of the clinical question being
asked (e.g. diagnosis of microdeletion of the Y chromo-
some), and the indication (e.g. azoospermia, ICSI, etc.).
• Tissue studied (e.g. blood, buccal smear, etc).
• Method used (e.g. multiplex PCR amplification).
• Outcome of the analysis: a tabular form of the various STS
loci analysed is preferred. Avoid the use of + and ), which
can be misinterpreted. Use words instead (e.g. present/
absent, or similar).
• A written interpretation understandable by the non-
specialist.
• Signature of at least one person responsible for the results.
Preferably, all laboratory data are reviewed and all outgoing
reports are signed by two independent assessors.
External quality assessment
The laboratories performing AZF diagnostics should join
an external quality assessment (EQA) scheme. It is funda-
mental that the DNA samples received from the organizers
of the EQA programme are processed exactly in the same
way as patients samples are handled, including reporting.
Results should be returned by mail to the organizers as
patient (i.e. DNA sample) reports written in English. E-mail
or fax can be used for quick communication, but the final
evaluation of the results will be performed exclusively on
reports received by mail.
Assessment of the performance of the laboratories
participating in the international quality control assessment
scheme organized by the EAA and EMQN includes both a
general report and individual reports and recommendations
to the participants. The results are assessed by independent
reviewers. Laboratories, which correctly diagnose and report
about the EQA samples receive a certificate.
Clinical relevance of partial deletions
and rearrangements of AZFc
Very recent data indicate that partial deletions of the
AZFc region (Repping et al., 2003; Vogt & Fernandes,
2003) and possibly other types of rearrangements (Fernandes
et al., 2004; Repping et al., 2004) occur relatively fre-
quently. While some of these deletions and rearrangements
might be of clinical significance, the exact role of such
findings in male infertility has not yet been comprehensively
analysed. Therefore, this should still be regarded as a very
experimental area of infertility genetics and more data are
necessary before clear-cut indications can be given for
clinical routine.
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Appendix A
Example of a PCR protocol
Two multiplex reactions were designed for the analysis of
the three AZF deletion regions on the Y chromosome. Both
multiplexes contain five fragments, i.e. the three AZF loci
and the two control fragments SRY and ZFY. Each
laboratory should set up and validate its own protocol. Here
we give an example of the protocol validated and currently
in use at the Institute of Reproductive Medicine in Mu¨nster.
PCR kit: Quiagen Multiplex PCR Kit (Cat.No. 206143,
Quiagen, Hilden, Germany).
Preparation of 10x primer mix A and B (containing 2 lM
each primer). Primer mixes are prepared in batches sufficient
for about 100 reactions, and packaged in smaller size aliquots
(sufficient for 10 or 20 reactions) for storage at )20 C.
The 50 lL PCR reaction mix contains:
25 lL 2x Quiagen Multiplex PCR MasterMix [contain-
ing HotStarTaq DNA Polymerase, Qiagen Multiplex PCR
Buffer (containing 6 mM MgCl2) and dNTP Mix], 5 lL 10x
Primer mix (2 lM each primer), approximately 1 lg
template DNA, sterile distilled water to 50 lL.
Amplification conditions (as established using a Hybaid
Touch Down Thermocycler, Dynex Hybald Lab System,
Frankfurt, Germany) start with an initial activation step of
15 min at 95 C, followed by 35 cycles of 30 sec denatur-
ation (94 C), 90 sec annealing (57 C) and 60 sec elonga-
tion (72 C), ended by a last elongation step of 10 min and
cooling to 4 C.
Reaction products (30 lL) are separated on a 2% Agarose
(Peqbold Universal Agarose, Peqlab, Erlangen, Germany)
plus 0.5% DNA Agar (Serva, Heidelberg, Germany) gels in
1 · TBE for 25 V overnight. An example of both multi-
plexes is given in Fig. 2.
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Appendix B
Sequence of the PCR primers
Multiplex Primers
A and B ZFY-F: 5¢ - ACC RCT GTA CTG ACT GTG ATT ACA C - 3¢
ZFY-R: 5¢ - GCA CYT CTT TGG TAT CYG AGA AAG T - 3¢
A and B SRY -F: 5¢ - GAA TAT TCC CGC TCT CCG GA - 3¢
SRY -R: 5¢ - GCT GGT GCT CCA TTC TTG AG - 3¢
A. sY86-F: 5¢ - GTG ACA CAC AGA CTA TGC TTC - 3¢
sY86-R: 5¢ - ACA CAC AGA GGG ACA ACC CT - 3¢
A. sY127-F: 5¢ - GGC TCA CAA ACG AAA AGA AA - 3¢
sY127-R: 5¢ - CTG CAG GCA GTA ATA AGG GA - 3¢
A. sY254-F: 5¢ - GGG TGT TAC CAG AAG GCA AA - 3¢
sY254-R: 5¢ - GAA CCG TAT CTA CCA AAG CAG C - 3¢
B. sY84-F: 5¢ - AGA AGG GTC TGA AAG CAG GT - 3¢
sY84-R: 5¢ - GCC TAC TAC CTG GAG GCT TC - 3¢
B. sY134-F: 5¢ - GTC TGC CTC ACC ATA AAA CG - 3¢
sY134-R: 5¢ - ACC ACT GCC AAA ACT TTC AA - 3¢
B. sY255-F: 5¢ - GTT ACA GGA TTC GGC GTG AT - 3¢
sY255-R: 5¢ - CTC GTC ATG TGC AGC CAC- 3¢
Appendix C
Useful web sites:
European Academy of Andrology (EAA):
http://www.uni-leipzig.de/eaa/index.html
European Molecular Genetics Quality Network
(EMQN):
http://www.emqn.org/
E-mail addresses of the authors:
M. Simoni: simoni@uni-muenster.de
E. Bakker: e.bakker@lumc.nl
C. Krausz: c.krausz@dfc.unifi.it
 1    2    3    4    5    6
 1    2    3    4    5   6
Multiplex A:  
ZFY :  495 bp 
SRY :  472 bp 
sY254 :  400 bp (AZFc)
 sY86 :  320 bp (AZFa)
sY127 :  274 bp (AZFb)
Multiplex B: 
ZFY :  495 bp 
SRY :  472 bp 
 sY84 :  326 bp (AZFa)
 sY134 :  301 bp (AZFb)
 sY255 :  126 bp (AZFc)
Figure 2. Examples of both Multiplex PCR. Multiplex A: lane 1, phi
X-HeaIII size marker; lane 2, water; lane 3, female DNA; lane 4, DNA of
normal male; lane 5, DNA of AZFb (P5/proximal P1)-deleted patient; lane 6,
DNA of AZFc (b2/b4)-deleted patient.
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